Buy & Sell Gap Inc (GAP) – Gap Inc Price Today
Key Stats
- $7.69BMarket Cap
- Consumer CyclicalSector
- -26.94%3M Drawdown
- $10.30BEnterprise Value
- 3.33%Dividend Yield
- 100% Buy | 0% SellTrading Activity
- 37 daysTypical Hold Time
Gap Inc (GAP) is currently valued at a market capitalization of $7.69B, with an enterprise value of $10.30B. Over the past 52 weeks, Gap Inc has traded between a low of $18.84 and a high of $29.13, highlighting its annual price range. Over the past three months, Gap Inc has recorded a drawdown of -26.94%, reflecting recent price volatility. Gap Inc offers a dividend yield of 3.33%, with the most recent dividend of $0.18 paid on 08 Apr 26. On average, investors hold Gap Inc for approximately 37 days, indicating typical investor behavior on the platform.
About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Most Recent News
Boston Scientific invests $1.5B for stake in MiRus, targeting advanced aortic stenosis treatment.
Boston Scientific has invested $1.5 billion to acquire about a 34% stake in MiRus, gaining exclusive rights to its investigational transcatheter aortic valve replacement (TAVR) system designed for severe aortic stenosis. The SIEGEL valve features a n...
Elliott sees hidden value in Bio-Rad via $5B Sartorius stake amid share price slump
Activist investor Elliott Investment Management has taken a significant stake in Bio-Rad Laboratories, which develops medical instruments and software. Bio-Rad's founding family retains majority voting control, complicating activist efforts. Elliott ...
Regeneron's melanoma trial fails, stock drops over 10%, investors urged to explore legal options.
Regeneron Pharmaceuticals announced that its Phase 3 melanoma trial combining fianlimab and Libtayo did not meet the primary endpoint against Keytruda, causing the stock to fall more than 10%. Prior optimism from company executives about the trial's ...
